Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 6
1992 39
1993 42
1994 66
1995 76
1996 86
1997 77
1998 71
1999 78
2000 71
2001 51
2002 32
2003 40
2004 35
2005 37
2006 42
2007 38
2008 44
2009 40
2010 50
2011 55
2012 53
2013 45
2014 39
2015 63
2016 54
2017 41
2018 42
2019 33
2020 44
2021 35
2022 33
2023 40
2024 13
2025 32
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,550 results

Results by year

Filters applied: . Clear all
Page 1
The Angiotensin-Converting-Enzyme-Induced Angioedema.
Bas M. Bas M. Immunol Allergy Clin North Am. 2017 Feb;37(1):183-200. doi: 10.1016/j.iac.2016.08.011. Immunol Allergy Clin North Am. 2017. PMID: 27886906 Review.
The bradykinin B2 receptor antagonist icatibant is effective in angiotensin-converting enzyme inhibitor-induced angioedema. The drug is not approved officially for this indication and has to be administered in an emergency situation off-label. ...
The bradykinin B2 receptor antagonist icatibant is effective in angiotensin-converting enzyme inhibitor-induced angioedema. The drug …
Reply.
Sinert R, Levy P, Bernstein JA, Body R, Sivilotti MLA, Moellman J, Schranz J, Baptista J, Kimura A, Nothaft W; CAMEO study group. Sinert R, et al. J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1803-1804. doi: 10.1016/j.jaip.2017.07.040. J Allergy Clin Immunol Pract. 2017. PMID: 29122164 Free article. No abstract available.
ACE inhibitor-mediated angioedema.
Montinaro V, Cicardi M. Montinaro V, et al. Int Immunopharmacol. 2020 Jan;78:106081. doi: 10.1016/j.intimp.2019.106081. Epub 2019 Dec 10. Int Immunopharmacol. 2020. PMID: 31835086 Review.
Interventional studies with the specific bradykinin receptor antagonist icatibant have shown conflicting results; there might be a different ethnic predisposition to icatibant efficacy which has been proven in caucasian but not in black patients....
Interventional studies with the specific bradykinin receptor antagonist icatibant have shown conflicting results; there might be a di …
Icatibant.
Deeks ED. Deeks ED. Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000. Drugs. 2010. PMID: 20030426
Icatibant is a selective antagonist of the bradykinin type 2 receptor. In the randomized, double-blind, multicentre, FAST-1 trial, the difference in the median time to the onset of symptom relief (primary endpoint) did not reach statistical significance between a single do …
Icatibant is a selective antagonist of the bradykinin type 2 receptor. In the randomized, double-blind, multicentre, FAST-1 trial, th …
Icatibant.
Dubois EA, Cohen AF. Dubois EA, et al. Br J Clin Pharmacol. 2010 May;69(5):425-6. doi: 10.1111/j.1365-2125.2010.03642.x. Br J Clin Pharmacol. 2010. PMID: 20573077 Free PMC article. No abstract available.
Recurrent Retroperitoneal Angioedema.
Wu MA, Ippolito S, Zanichelli A, Perego F, Cicardi M. Wu MA, et al. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1384-1385. doi: 10.1016/j.jaip.2018.04.019. Epub 2018 May 3. J Allergy Clin Immunol Pract. 2018. PMID: 29729442 No abstract available.
Icatibant in viral infections.
Mustonen J, Antonen J, Vaheri A. Mustonen J, et al. Infect Dis (Lond). 2023 Jun;55(6):444-445. doi: 10.1080/23744235.2023.2200563. Epub 2023 Apr 17. Infect Dis (Lond). 2023. PMID: 37067851 No abstract available.
Treatment of Hereditary Angioedema.
Caballero T. Caballero T. J Investig Allergol Clin Immunol. 2021 Feb;31(1):1-16. doi: 10.18176/jiaci.0653. J Investig Allergol Clin Immunol. 2021. PMID: 33602658 Free article. Review.
The 4 drugs that are currently available for the treatment of acute angioedema attacks (purified plasma-derived human C1 esterase inhibitor concentrate, icatibant acetate, ecallantide, recombinant human C1 esterase inhibitor) are all authorized for self-administration, exc …
The 4 drugs that are currently available for the treatment of acute angioedema attacks (purified plasma-derived human C1 esterase inhibitor …
New Treatments for Hereditary Angioedema.
Johnson NM, Phillips MA. Johnson NM, et al. Skin Therapy Lett. 2018 Jan;23(1):6-8. Skin Therapy Lett. 2018. PMID: 29357215 Free article. Review.
The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
Maurer M, Aberer W, Caballero T, Bouillet L, Grumach AS, Botha J, Andresen I, Longhurst HJ; IOS Study Group. Maurer M, et al. Clin Exp Allergy. 2022 Sep;52(9):1048-1058. doi: 10.1111/cea.14206. Epub 2022 Aug 7. Clin Exp Allergy. 2022. PMID: 35861129 Review.
In patients with hereditary angioedema (HAE), bradykinin causes swelling episodes by activating bradykinin B(2) receptors. Icatibant, a selective bradykinin B(2) receptor antagonist, is approved for on-demand treatment of HAE attacks. The Icatibant Outcome Survey (I …
In patients with hereditary angioedema (HAE), bradykinin causes swelling episodes by activating bradykinin B(2) receptors. Icatibant, …
1,550 results